Nymox: study finds that statin drugs protect against cognitive decline

By Lisa Kerner

Charlotte, N.C., July 19 - Nymox Pharmaceutical Corp. said a study presented at the 10th International Conference on Alzheimer's Disease and Related Disorders in Madrid found that use of statin drugs significantly protected against cognitive decline in elderly African Americans.

Researchers measured the rate of cognitive decline in 1,149 elderly non-demented African Americans over the age of 70 over a three-year period. The average rate of decline for statin drug users was over 70% less than non-users, according to a company news release.

Nymox holds U.S. and global patent rights for the use of statins, a class of cholesterol-lowering drugs, for the prevention and treatment of Alzheimer's disease.

Located in Hasbrouck Heights, N.J., Nymox is a biopharmaceutical company specializing in therapeutics and diagnostics for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.